Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 136,942 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 136,942 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $36.73, for a total transaction of $5,029,879.66. Following the completion of the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at $684,307,043.47. The trade was a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total transaction of $10,320,628.75.

Roivant Sciences Stock Up 3.1%

Shares of ROIV stock opened at $37.37 on Wednesday. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.46. The firm has a fifty day moving average of $34.16 and a 200-day moving average of $30.17. The firm has a market capitalization of $26.99 billion, a price-to-earnings ratio of -70.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its position in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Roivant Sciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after purchasing an additional 3,254,113 shares during the last quarter. Rubric Capital Management LP lifted its position in shares of Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after purchasing an additional 2,603,260 shares in the last quarter. State Street Corp lifted its position in shares of Roivant Sciences by 4.8% in the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after purchasing an additional 911,827 shares in the last quarter. Finally, UBS Group AG boosted its holdings in Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after purchasing an additional 15,645,836 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of research analyst reports. Guggenheim raised their price target on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.